You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
N/A
SBC: ABACUS HEALTH SOLUTIONS, LLC Topic: N/AN/A
STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health -
Inhibition of methanogenesis
SBC: BIONEBRASKA, INC. Topic: N/ADESCRIPTION:(provided by applicant) The goal of this project is to develop a novel inhibitor of methane formation in ruminant animals. Currently, monensin, a relatively nonspecific antibiotic, is widely used in the livestock industry. Monensin increases agricultural productivity by decreasing methane and increasing propionate production; however, it also inhibits ...
STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
TARGETING STEALTH LIPOSOME FOR CANCER GENE THERAPY
SBC: SYNERGENE THERAPEUTICS, INC. Topic: N/AAdvanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents, and this chemoresistance correlates with a lack of functional p53. Our preliminary data indicate that cancer cells can be sensitize to chemotherapy via p53 replacement using a tumor-targeting liposomal delivery system. The low stability and rapid clearance from circulation of these ligand-liposomes are ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER
SBC: SYNERGENE THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack of functional p53. Our previous data indicate that cancer cells can be sensitized to radiation and chemotherapy via p53 replacement using a tumor-targeting liposomal delivery system. In the STTR Phase ...
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health -
IMMUNOLIPOSOME-MEDIATED GENE THERAPY FOR PROSTATE CANCER
SBC: SYNERGENE THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Advanced prostate cancer tends to be relatively refractory to standard chemotherapeutic agents and radiation treatment, and this resistance correlates with a lack of functional p53. Our previous data indicate that cancer cells can be sensitized to radiation and chemotherapy via p53 replacement using a tumor-targeting liposomal delivery system. In the STTR Phase ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
Transmucosal Intra-Oral Drug Delivery System for THC
SBC: ElSohly Laboratories, Incorporated Topic: N/ADESCRIPTION (provided by applicant): The overall goal of this research project is to develop an effective, hot-melt extruded "Transmucosal Matrix Patch" (TMP) as a delivery system for Delta-9-Tetrahydrocannabinol (THC). THC will be incorporated into a stable, bioadhesive drug delivery system that is applied to a subject's buccal or labial oral mucosa. The controlled release of THC is delivered to ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
OTOREFLECTANCE ASSESSMENT OF MIDDLE-EAR FUNCTIONING
SBC: Sonicom, Inc. Topic: N/ADESCRIPTION (provided by applicant): Otoreflectance (OR) is a new class of hearing test instruments utilizing acoustic signals presented and recorded in the ear canal. OR instruments address limitations in existing screening and diagnostic instruments in such areas as: (1) detecting otitis media, (2) predicting conductive hearing loss, (3) augmenting the newborn hearing screening protocol to test ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
A Dual Molecular/Targeting Therapy for PanCa
SBC: SYNERGENE THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic Cancer (PanCa). Over 90% of these will die of the disease making PanCa one of the most devastating human malignancies. The current 5-year survival rate of less than 4% has changed little in the last 20 years despite improvements in therapy including the introduction of chem ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
Generation of Human Hepatocytes
SBC: IN VIVO TECHNOLOGIES Topic: N/ADESCRIPTION (provided by applicant): The goal of this project is to produce "humanized" livers in large animal models such as sheep and pigs that can serve as a reliable source of significant numbers of functional human hepatocytes. The isolated human hepatocytes and/or "humanized" livers can be used for drug toxicity studies as well as for possible clinical use in patients with liver failure. Tra ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
A Peptide-Based Vaccine to Nicotine
SBC: Prommune, Inc. Topic: N/ADESCRIPTION (provided by applicant): The primary objective of this Phase I STTR project is to develop an effective, peptide-based nicotine vaccine for use in humans capable of inducing a robust, nicotine-specific antibody (Ab) response with little or no inflammatory side effects. This will be accomplished by a vaccine design in which a conformationally biased, response-selective agonist Of C5a ( ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
